KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Non-Current Debt (2016 - 2026)

Amgen has reported Non-Current Debt over the past 18 years, most recently at $51.9 billion for Q1 2026.

  • For Q1 2026, Non-Current Debt fell 3.94% year-over-year to $51.9 billion; the TTM value through Mar 2026 reached $51.9 billion, down 3.94%, while the annual FY2025 figure was $50.0 billion, 11.57% down from the prior year.
  • Non-Current Debt for Q1 2026 was $51.9 billion at Amgen, up from $50.0 billion in the prior quarter.
  • Over five years, Non-Current Debt peaked at $63.2 billion in Q4 2023 and troughed at $35.7 billion in Q2 2022.
  • A 5-year average of $51.8 billion and a median of $54.0 billion in 2025 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 69.11% in 2023 and later fell 11.57% in 2025.
  • Year by year, Non-Current Debt stood at $37.4 billion in 2022, then skyrocketed by 69.11% to $63.2 billion in 2023, then decreased by 10.48% to $56.5 billion in 2024, then dropped by 11.57% to $50.0 billion in 2025, then grew by 3.76% to $51.9 billion in 2026.
  • Business Quant data shows Non-Current Debt for AMGN at $51.9 billion in Q1 2026, $50.0 billion in Q4 2025, and $52.4 billion in Q3 2025.